Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Over the past decade, artificial intelligence (AI) and automation have reshaped clinical research. From identifying drug ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how AI is stepping in to fill staffing gaps in ...

Why future-ready pharma companies must embrace AI-driven, real-time decision-making. Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how clinical trial sites and sponsors are responding to funding constraints by turning to telemedicine, cost-containment ...

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.

With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how staffing reductions caused by clinical trial budget cuts are threatening patient recruitment and retention and warns of ...